Rushabh K. Kothari

Ahmedabad, GJ 380007, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Assessment of drug utilization patterns and associated survival outcomes in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Insights from a resource-constrained set-up.

Assessment of drug utilization patterns and associated survival outcomes in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Insights from a resource-constrained set-up.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 14, 2026

Effectiveness and safety of first-line therapies, dual immunotherapy versus immunotherapy plus targeted therapy in advanced renal cell carcinoma: A systematic review and meta-analysis.

Effectiveness and safety of first-line therapies, dual immunotherapy versus immunotherapy plus targeted therapy in advanced renal cell carcinoma: A systematic review and meta-analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 15, 2026

Practice Patterns and Outcomes in Advanced Colorectal Cancers From a Multi-Institutional Analysis: Real-World Evidence From India.

Practice Patterns and Outcomes in Advanced Colorectal Cancers From a Multi-Institutional Analysis: Real-World Evidence From India.

Journal: JCO global oncology

Published: November 19, 2025

Comparative pooled analysis of targeted therapies, or immunotherapy plus chemotherapies versus conventional platinum-based therapies or single-agent immunotherapies in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Comparative pooled analysis of targeted therapies, or immunotherapy plus chemotherapies versus conventional platinum-based therapies or single-agent immunotherapies in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: October 22, 2025

A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients.

A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients.

Journal: Head & neck

Published: July 24, 2025

Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms.

Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms.

Journal: Journal of drug targeting

Published: June 26, 2025

A real-world study of the effectiveness and safety of low-dose immunotherapy in addition to oral metronomic chemotherapy in recurrent and metastatic head and neck squamous cell carcinoma.

A real-world study of the effectiveness and safety of low-dose immunotherapy in addition to oral metronomic chemotherapy in recurrent and metastatic head and neck squamous cell carcinoma.

Journal: Journal of the Egyptian National Cancer Institute

Published: May 12, 2025

Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes.

Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes.

Journal: Cancer letters

Published: January 16, 2025

Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.

Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study.

Journal: Clinical drug investigation

Published: June 03, 2024

Prevalence and types of cancer in older Indians: A multicentric observational study across 17 institutions in India.

Prevalence and types of cancer in older Indians: A multicentric observational study across 17 institutions in India.

Journal: Cancer epidemiology

Published: March 27, 2024

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: March 11, 2024

Prognostic value of tumour-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis.

Prognostic value of tumour-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis.

Journal: Systematic reviews

Published: February 11, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026